| Clinical Study "Common" Name (formal title) | Number of enrollees | Funding source (pharma/NIH) | Year complete | Primary publication | Full study treatment protocol |
|---|---|---|---|---|---|
| PULSAR [Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: 156-Week Results From the PULSAR Extension] | n = 625 |
Regeneron/Bayer NCT04423718 |
Primary completion: 2022 Study completion: 2024 |
Wong T. Aflibercept 8 mg in neovascular age-related macular degeneration: 156-week results from the PULSAR extension. Presented at: Macula Society 2025; February 15, 2025; Charlotte Harbour, FL. Accessed February 25, 2025. |
|